Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.
Key Takeaways Intensifying global pricing reforms, increasing biosimilar competition, and mounting regulatory demands will significantly pressure Roche's revenue, margins, and long-term profitability. Rising R&D costs, disruptive new technologies, and shifting payer priorities threaten Roche's innovation pipeline and ability to sustain premium pricing for novel therapies.
Key Takeaways Expanding innovative diagnostics and advancing high-value biologics pipelines position Roche for strong global growth and resilient revenues across diverse markets. Strategic investments in automation, AI, and emerging markets drive margin expansion, lower costs, and reduce reliance on older, patent-sensitive products.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
